Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 18, 2019 - The FDA approved Samsung Bioepis and Merck’s Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin® (trastuzumab).
Return to publications